Review reveals how Fusobacterium drives inflammation and cancer along the oral-gut axis, highlighting opportunities for microbiome-targeted therapies.
Fusobacterium functions as both commensal and pathogen, linking the oral-gut axis to diverse diseases, including cancer. Evidence shows it modulates microbial balance, promotes dysbiosis, and contributes to carcinogenesis by driving inflammation, proliferation, invasion, and immune evasion. This review integrates ecological, molecular, and clinical insights, highlighting its roles in oral and systemic disease and discussing therapeutic potential, underscoring Fusobacterium's dualistic nature and implications for microbiome-targeted interventions.
No takes yet. Share an insight, caveat, or question.
Li et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: